New Data on Needle Free Epinephrine Spray Presented at ACAAI 2024
A summary of new data presented at the 2024 American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
ARS Pharmaceuticals is presenting new data October 25 on the first needle-free epinephrine nasal spray (neffy) for treating Type I allergic reactions, at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
These presentations will showcase a number of posters covering topics such as cardiovascular safety, human factor research for emergency readiness, and real-world data in pediatric patients.
The above slideshow features a snapshot of the presentations being featured at the ACAAI meeting, with links to view the posters.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
